Rhythm Biosciences Ltd
Rhythm Biosciences Ltd (ASX:RHY) is listed on the Australian Securities Exchange.
See more information about Rhythm Biosciences Ltd
Rhythm Biosciences makes progress in developing colorectal cancer test
Rhythm Biosciences Ltd (ASX:RHY) has completed an important step in the development of its antibody-based blood test, ColoSTAT, targeting the accurate and early detection of colorectal cancer.
The company's shares are trading about 5.5% higher intra-day at 19 cents after successfully preparing four monoclonal antibodies which have passed all three preliminary screening tests.
Proprietary algorithm to measure cancer risk
Colorectal cancer is the second largest cause of cancer-related deaths in Australia, Europe and the US, and the third largest globally.
ColoSTAT uses antibodies to measure the levels of several proteins in the blood. The concentrations of these proteins in blood have been shown to vary in the presence or absence of colorectal cancer.
When these concentration values are combined using a proprietary algorithm the resultant cancer risk index is compared to a pre-determined threshold value.
An index value above the threshold suggests the patient should progress to colonoscopy for a definitive diagnosis and further intervention as indicated.
